Peptidream Inc., of Kanagawa, Japan, disclosed a new peptide-drug conjugate (PDC) collaboration agreement with Novartis AG, of Basel, Switzerland. Peptidream will use its Peptide Discovery Platform System technology for the identification of macrocyclic/constrained peptides for use as PDCs against multiple targets of interest selected by Novartis.